Core Insights - United Therapeutics Corp reported fourth-quarter earnings of $7.70 per share, exceeding the analyst consensus estimate of $7.09 per share [1] - The company’s quarterly sales were $790.200 million, which fell short of the analyst consensus estimate of $813.077 million [1] Group 1: Financial Performance - The earnings per share of $7.70 represents a positive surprise compared to expectations [1] - Quarterly sales of $790.200 million indicate a revenue miss relative to analyst forecasts [1] Group 2: Management Commentary - Martine Rothblatt, CEO, highlighted the achievement of record total revenue for the fourth consecutive year and expressed gratitude to employees for their commitment [2] - The CEO mentioned upcoming clinical programs, ADVANCE OUTCOMES and TETON-1, which are expected to provide pivotal data for new treatment options, signaling potential growth for the company [2] Group 3: Market Reaction - Following the earnings announcement, United Therapeutics shares declined by 5.6%, trading at $505.28 [2]